preload preload preload preload preload preload preload preload preload

Molecular Response logo

Tumor Bank

Molecular Response has the world’s largest bank of viable cryopreserved tumor cells. The bank contains more than 144,000 tumor specimens, covering 25 tissue types and 76 clinical diagnoses (Table 1). Each of the specimens contains viable tumor cells that were cryfrozen as single cell suspensions for culture.

The bank was collected over the past 20 years from a US population, with matched histology/path review and associated ex-vivo treatment data for each specimen.

Additionally, each specimen has matching DNA, RNA and protein available for screening targets of interest in order to identify particular tumor cases for subsequent studies, including ex vivo and in vivo drug screens.


INDICATIONS

The Molecular Response Tumor Bank features tumors from virtually all known–common and rare–cancer indications. Major cancer types such as breast, lung, colon, and ovarian average >10,000 specimens per indication. Less common cancers are also prominently featured, including small cell lung and neuroendocrine, for example. See Table 1A and 1B for a complete list of tumor types.


DRUG RESPONSE DATA

Each of the specimens in the tumor bank has been profiled against a panel of drugs ex vivo, and levels of resistance recorded; we leverage the drug resistance data to select tumor cells of interest for our partners’ drug treatment studies and molecular marker discovery. See Table 2 for a complete list of drugs screened per indication.


APPLICATIONS

Tumor Bank Applications:


Table 1A. Tumor specimens by tissue type:

Bladder

 

Brain

Breast

Cervix

Colon

Endocrine

GI

Head & Neck

Leukemia

Liver

Lung (non small cell)

Lung (small cell)

Lymphoid

Lymphoma

Mesothelioma

Myeloma

 

Nervous

Neuroendocrine

Oral

Other

Ovarian

Pancreas

Prostate

Renal

Sarcoma

Skin

Squamous carcinoma

Testicular

Uterus

Table 1B. Tumor specimens by clinical diagnosis:

Acute lymphocytic leukemia

 

Acute non-lymphocytic leukemia

Adrenal carcinoma

Anemia, pancytopenia

Appendiceal carcinoma

Basal cell carcinoma

Benign

Bladder carcinoma

Brain tumor

Breast carcinoma

Carcinoid tumor

Cervical carcinoma

Choriocarcinoma

Chronic lymphocytic leukemia

Chronic myelogenous leukemia

CNS tumor

Colon carcinoma

Desmoplastic small round cell

Endometrial carcinoma

Esophageal carcinoma

Ewing’s sarcoma

Fallopian tube carcinoma

Gallbladder carcinoma

Gastrointestinal stromal tumor

Granulosa cell tumor

Hairy cell leukemia

Hodgkin’s lymphoma

 

Kidney carcinoma

Liver carcinoma

Lymphoproliferative disorder

Malignant fibrous histiocytoma

Malignant melanoma

Malignant mesothelioma

Merkel cell carcinoma

Miscellaneous tumor

Mixed mullerian tumor

Multiple myeloma

Myelodysplastic syndromes

Neuroblastoma

Neuroendocrine tumor

Non-Hodgkin’s lymphoma

Non-small cell lung cancer

Osteosarcoma

Ovarian (Small Cell)

Ovarian carcinoma

Ovarian germ cell tumor

Ovarian LMP

Ovarian sarcoma

Pancreatic carcinoma

Parotid gland carcinoma

Peritoneal carcinoma

Primitive neuroectodermal

Prostate carcinoma

 

Pseudomyxoma peritonei

R/O malignant lymphoma

Salivary gland carcinoma

Sarcoma

Small cell carcinoma

Small intestine carcinoma

Squamous carcinoma of cervix

Squamous carcinoma of H&N

Squamous cell carcinoma

Squamous cell carcinoma, UPS

Squamous cell vulva

Stomach carcinoma

Testicular germ cell tumor

Thymoma

Thyroid carcinoma

Transitional cell kidney

Unknown primary site

Unknown primary site, gyn

Unknown, not provided

Uterine sarcoma

Vaginal carcinoma

Waldenstrom macroglobulinemia

Wilm’s tumor

Table 2. Drug panels by indication:

 

ANLL
1. Daunorubicin

 

2. Cytarabine

3. Mitoxantrone

4. Idarubicin

5. Carboplatin

6. Etoposide

7. Fludarabine

8. Topotecan


Lung (Non-Small Cell)

1. Carboplatin

2. Taxol

3. Navelbine

4. Etoposide

5. Gemcitabine

6. Topotecan

7. Cisplatin

8. Taxotere


Renal Cell

1. Interleukin 2

2. Alpha-Interferon

3. Fluorouracil

4. Gemcitabine

5. Doxil

6. Vinblastine

7. Interferon + Vinblastine

8. Mitomycin C

9. Cyclophosphamide

Breast
1. Doxorubicin

 

2. Cyclophosphamide

3. Taxol

4. Fluorouracil

5. Navelbine

6. Taxotere

7. Gemcitabine

8. Cisplatin

9. Capecitabine


Melanoma

1. Cisplatin

2. Temozolomide

3. Vinblastine

4. Taxotere

5. Navelbine

6. Gemcitabine

7. Navelbine + Taxotere

8. Alpha-Interferon

9. Carmustine


Sarcoma

1. Doxorubicin

2. Ifosfamide

3. Temozolomide

4. Cisplatin

5. Taxotere

6. Gemcitabine

7. Topotecan

Colorectal
1. 5 FU + Leucovorin

 

2. Irinotecan

3. 5 FU + Irinotecan

4. Oxaliplatin

5. Topotecan

6. Capecitabine

7. Floxuridine

Endometrial

1. Cisplatin

2. Taxol

3. Doxorubicin

4. Ifosfamide

5. Etoposide

6. Cyclophosphamide

7. Topotecan


Non-Hodgkin’­s Lymphoma

1. Cyclophosphamide

2. Doxorubicin

3. Vincristine

4. Dexamethasone

5. Etoposide

6. Bleomycin

7. Cytarabine

CLL
1. Fludarabine

 

2. Cyclophosphamide

3. Dexamethasone

4. Doxorubicin

5. Vincristine

6. Melphalan

7. Cladribine

Multiple Myeloma

1. Melphalan

2. Vincristine

3. Doxorubicin

4. Dexamethasone

5. Cyclophosphamide

6. Carmustine

7. Etoposide

8. Alpha-Interferon


Squamous

1. Cisplatin

2. Ifosfmide

3. Etoposide

4. Fluorouracil

5. Cyclophosphamide

6. Doxorubicin

7. Taxol

Ovarian
1. Carboplatin

 

2. Taxol

3. Topotecan

4. Doxil

5. Etoposide

6. Gemcitabine

7. Taxotere

8. Cisplatin

9. Cisplatin + Gemcitabine

10. Cyclophosphamide


Stomach/Gastric

1. Fluorouracil

2. Mitomycin C

3. Doxorubicin

4. Cisplatin

5. Etoposide

6. Gemcitabine

7. Taxol


Unknown Primary Site

1. Cisplatin

2. Doxorubicin

3. Fluorouracil

4. Cyclophosphamide

5. Taxol

6. Topotecan

7. Etoposide